|1.||Rigas, Basil: 5 articles (06/2006 - 12/2002)|
|2.||Williams, Jennie L: 3 articles (07/2012 - 12/2002)|
|3.||Traganos, Frank: 3 articles (08/2006 - 12/2002)|
|4.||Kashfi, Khosrow: 3 articles (07/2004 - 12/2002)|
|5.||Cisterne, Adam: 2 articles (01/2014 - 03/2012)|
|6.||Baraz, Rana: 2 articles (01/2014 - 03/2012)|
|7.||Bradstock, Kenneth F: 2 articles (01/2014 - 03/2012)|
|8.||Khan, Naveed I: 2 articles (01/2014 - 03/2012)|
|9.||Bendall, Linda J: 2 articles (01/2014 - 03/2012)|
|10.||Steele, Vernon E: 2 articles (09/2012 - 06/2006)|
09/01/2012 - "Our results reveal that NO-aspirin at 1000 and 2000 ppm significantly suppressed pancreatic tumor weights, PDAC incidence, and carcinoma in situ (PanIN-3 lesions). "
04/18/2007 - "Overall cancer incidence per 100,000 person-years (standardized to the age distributions of men and women in the study) with long-term daily aspirin use and no aspirin use was 1858 and 2163, respectively, among men and 1083 and 1169, respectively, among women. "
06/01/2006 - "Our results suggest that NO-indomethacin at 40 and 80 ppm and NO-aspirin at 3,000 ppm significantly suppressed both tumor incidence (P < 0.01) and multiplicity (P < 0.001). "
01/01/2006 - "NO-aspirin seems safer and in cultured cancer cells it is >1000-fold more potent than aspirin. "
06/15/2005 - "Animals given aspirin for 6 days before, or at the time of, orthotopic tumor cell injection showed a significantly lower incidence of tumor formation compared with those receiving aspirin 2 weeks after inoculation and controls receiving no aspirin. "
|2.||Colonic Neoplasms (Colon Cancer)
01/01/2007 - "In the present study, we investigated the mechanisms underlying the cytotoxicity of NCX 4040, a novel NO-aspirin with promising antineoplastic action, in in vitro human colon cancer models. "
06/15/2004 - "Preclinical studies have shown that NO-aspirin (NO-ASA) is more potent than traditional ASA in preventing colon cancer. "
01/01/2006 - "Our data indicate that NO-aspirin is dependent on both the p38 and the JNK MAP kinase pathways for its ability to inhibit the growth of colon cancer cells."
01/01/2006 - "We used specific MAPK inhibitors, small interfering (siRNA) gene silencing methods, and dominant-negative cJun to determine the relevance of these phosphorylation events to the ability of NO-aspirin to inhibit colon cancer cell growth. "
01/01/2006 - "To determine the mechanism by which NO-aspirin inhibits cell growth, we studied its effect on mitogen-activated protein kinase (MAPK) signaling in HT-29 human colon cancer cells. "
07/24/1991 - "Among women who reported taking one through six aspirin per week, the age-adjusted relative risk (RR) of a first myocardial infarction was 0.68 (95% confidence interval [CI], 0.52 to 0.89; P = .005), as compared with those women who took no aspirin. "
12/17/2014 - "Patients with an occurrence of nonfatal stroke totaled 114 in the aspirin group and 108 in the no aspirin group; of nonfatal myocardial infarction, 20 in the aspirin group and 38 in the no aspirin group; of undefined cerebrovascular events, 3 in the aspirin group and 5 in the no aspirin group. "
12/17/2014 - "Aspirin significantly reduced incidence of nonfatal myocardial infarction (0.30 [95% CI, 0.19-0.47] for aspirin vs 0.58 [95% CI, 0.42-0.81] for no aspirin; HR, 0.53 [95% CI, 0.31-0.91]; P = .02) and transient ischemic attack (0.26 [95% CI, 0.16-0.42] for aspirin vs 0.49 [95% CI, 0.35-0.69] for no aspirin; HR, 0.57 [95% CI, 0.32-0.99]; P = .04), and significantly increased the risk of extracranial hemorrhage requiring transfusion or hospitalization (0.86 [95% CI, 0.67-1.11] for aspirin vs 0.51 [95% CI, 0.37-0.72] for no aspirin; HR, 1.85 [95% CI, 1.22-2.81]; P = .004). "
06/16/2005 - "The simultaneous release of aspirin and nitric oxide from the (*)NO-aspirin prodrugs constitutes a potentially beneficial property for the prophylactic prevention of thrombus formation and adverse cardiovascular events such as stroke and myocardial infarction. "
|4.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/01/2014 - "NO-aspirin is a novel drug that has efficacy against a number of solid tumours, and can inhibit Wnt signaling, and although we have shown Wnt signaling to be important for acute lymphoblastic leukemia (ALL) cell proliferation and survival inhibition of Wnt signaling does not appear to be involved in the induction of ALL cell death. "
03/01/2012 - "Para-NO-aspirin inhibits NF-κB and induces apoptosis in B-cell progenitor acute lymphoblastic leukemia."
09/01/2007 - "Moreover, NO-aspirin also improved ischemia-reperfusion-induced myocardial contractile dysfunction on postischemic LV developed pressure. "
09/01/2007 - "The beneficial effects of NO-aspirin appeared to be derived largely from the NO moiety, which attenuated myocardial injury to limit infarct size and better recovery of LV function following ischemia and reperfusion."
11/01/2005 - "The ischemia-induced reductions in cortical and medullary flux were ameliorated in the aspirin and NO-aspirin groups where flux fell to 96 and 78% and 105 and 83%, respectively (P < 0.05). "
|1.||Aspirin (Acetylsalicylic Acid)
|3.||Nitric Oxide (Nitrogen Monoxide)
|4.||Non-alcoholic Fatty Liver Disease
|8.||tranilast (N 5')
|9.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
|3.||Activities of Daily Living (ADL)